News

Latest news: Quotient Sciences Completes Integration of Drug Substance Into Translational Pharmaceutics Platform

Access Press Release

About us

Translational Pharmaceutics®

Quotient Sciences first brought meaningful innovation to the pharmaceutical industry in 2008 with Translational Pharmaceutics® – a unique delivery platform that shortens development times by more than 12 months.

By integrating drug substance, drug product and clinical testing activities, Translational Pharmaceutics® accelerates molecules through development. This saves time and money in reaching key milestones as quickly and efficiently as possible, ensuring better decision making and more streamlined outsourcing.

Drug_Substance-to-Drug_Product_Integration
  • Reducing the time from candidate selection to first in human
  • Accelerating molecules from first in human to proof of concept
  • Selecting and optimizing clinical formulations
  • Accelerating products through to commercial manufacture

Translational Pharmaceutics® has now been used by pharmaceutical and biotech companies on over 500 drug programs. The financial benefits and time savings were quantified in a publication by the Tufts Center for the Study of Drug Development.

What Our Clients Say

"Our small biotech company worked with Quotient Sciences on developing a complex formulation and validating the different iterations of the formulation in PK clinical studies using the Translational Pharmaceutics® approach. The project was successful, and we were generally impressed by the skillsets, professionalism, and courtesy of Quotient Sciences' scientists and other subject experts. We have also chosen to work with Quotient Sciences on two subsequent projects."

– Evecxia

Translational Pharmaceutics®

  • A faster approach to drug development and accelerated time to market
  • Timeline acceleration of >12 months
  • Significant reduction in R&D spend
  • Better decision making
  • Greater likelihood of success
  • Simplified supply chain
Get in touch
Humanity can’t afford to wait, so neither can we.
Let’s talk.